Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s

Bayer Q1 2024 net income drops 8.2% to € 2 billion

EBITDA before special items falls 1.3 percent to € 4.41 billion

Coveris invests over €8 million in production capacity

Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany

Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr

Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024

Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr

Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024

Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr

The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024

Dr. Lal PathLabs posts Q4 FY24 consolidated PAT at Rs. 84.5 Cr

The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024

Hester Biosciences posts Q4 FY24 consolidated profit increases to Rs. 4.95 Cr

The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024